{"id":"W2921877205","doi":"10.1093/jcag/gwz006.121","title":"A122 COMBINATION BIOLOGIC THERAPY IN INFLAMMATORY BOWEL DISEASE: THE CALGARY EXPERIENCE","year":2019,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Microscopic Colitis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Vedolizumab; Infliximab; Golimumab; Adalimumab; Ustekinumab; Ulcerative colitis; Internal medicine; Inflammatory bowel disease; Faecal calprotectin; Crohn's disease; Combination therapy; Biologic Agents; Certolizumab pegol; Gastroenterology; Disease; Calprotectin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063147,0.00006781208,0.0001950373,0.0001472252,0.00004318154,0.000009485646,0.0002201298,0.00007205474,0.0001305023],"category_scores_gemma":[0.0003059576,0.00004208243,0.0001079154,0.00007677541,0.0000598101,0.00005184599,0.00002011149,0.0002726259,0.000003686486],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001061221,"about_ca_system_score_gemma":0.0004432853,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002459151,"about_ca_topic_score_gemma":0.07023638,"domain_scores_codex":[0.9988409,0.0002908643,0.0003764105,0.0000710476,0.0002073698,0.0002134612],"domain_scores_gemma":[0.9988472,0.0000721476,0.0006064611,0.0001726369,0.0001854178,0.0001160768],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002473,0.00003010086,0.9972535,0.000007250329,0.00003375754,0.000007860427,0.0003517001,0.00001392434,0.0008883583,0.0001003281,0.0009631605,0.0001027484],"study_design_scores_gemma":[0.001840346,0.0004018659,0.9955953,0.00004939113,0.00001180731,0.00002423133,0.00007219498,0.00005360259,0.00005064043,0.0001308136,0.001748915,0.0000208642],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9801189,0.00006316036,0.000002620033,0.01888564,0.0005331538,0.0002617615,0.000005779085,0.000001683693,0.0001273592],"genre_scores_gemma":[0.99643,0.00004978669,0.00001396143,0.003018908,0.00004731938,0.000004078175,0.000001863106,0.000005235107,0.0004287818],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06777722,"threshold_uncertainty_score":0.9467294,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006995530574416766,"score_gpt":0.2350238210076898,"score_spread":0.228028290433273,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}